(Q41548239)

English

Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

author name string

E L Haseltine

1

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

M S Penney

2

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

S George

3

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

T L Kieffer

4

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

publication date

13 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

701-707

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Projecting future complications of chronic hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Clinical evidence for the regression of liver fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective st

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12382

21 January 2018

Identifiers

10.1111/JVH.12382

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

release_vvxikheblbaplli5rmvq4bobty

1 reference

https://api.fatcat.wiki/v0/release/vvxikheblbaplli5rmvq4bobty

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41548239&oldid=1924184205"